How to Make Electronic Submission a Business Benefit
This article was originally published in SRA
Executive Summary
Many companies think of the electronic common technical document for submissions as a mere electronification of the CTD. They believe that implementing the eCTD essentially removes the printing processes while adding new processes for PDF rendition, bookmarking, hyperlinking and generation of the XML backbone. While this conception is not mistaken, it ignores important business potentials that the eCTD can offer a pharmaceutical company. Substantial business benefits such as reductions in submission times and costs could be achieved by companies if they approached the implementation of the eCTD as an opportunity to rethink their entire process hierarchy.
You may also be interested in...
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.
GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows
A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.